Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy

Clinical and Experimental Nephrology

Volumn 18, Issue 5, 2014, Pages 770-777

  Suzuki, Yusuke ^a   Matsuzaki, Keiichi ^a   Suzuki, Hitoshi ^a   Okazaki, Keiko ^a   Yanagawa, Hiroyuki ^a   Ieiri, Norio ^b,c   Sato, Mitsuhiro ^b   Sato, Toshinobu ^b   Taguma, Yoshio ^b   Matsuoka, Joe ^d   Horikoshi, Satoshi ^a   Novak, Jan ^e   Hotta, Osamu ^b,c   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sendai Shakaihoken Hospital   (Japan)

^c Hotta Osamu Clinic   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

^e University of Alabama at Birmingham   (United States)

Author keywords

Biomarker; Disease activity; IgA nephropathy; Immune complex; Underglycosylated IgA

Indexed keywords

BIOLOGICAL MARKER; GALACTOSE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE; IMMUNOGLOBULIN A;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN BLOOD LEVEL; LONGITUDINAL STUDY; MALE; PROTEINURIA; REMISSION; TONSILLECTOMY; URINALYSIS; BLOOD; GLOMERULONEPHRITIS, IGA; METABOLISM; MIDDLE AGED;

ADULT; BIOMARKERS; CROSS-SECTIONAL STUDIES; FEMALE; GALACTOSE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TONSILLECTOMY;

EID: 84919326272     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0921-6     Document Type: Article

References (37)

1. D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–37.
2. Chauveau D, Droz D. Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol. 1993;104:1–5.
3. Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.
4. Shen P, He L, Li Y, et al. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106:c157–61.
5. Imai H, Miura N. A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission? Clin Exp Nephrol. 2011;16:195–201.
6. Donadio JV, Grande JP. IgA Nephropathy. N Engl J Med. 2002;347:738–48.
7. Maeda A, Gohda T, Funabiki K, et al. Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J Clin Lab Anal. 2003;17:73–6.
8. Nakayama K, Ohsawa I, Maeda-Ohtani A, et al. Prediction of diagnosis of immunoglobulin A nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading. J Clin Lab Anal. 2008;22:114–8.
9. Wakai K, Kawamura T, Endoh M, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006;21:2800–8.
10. Goto M, Wakai K, Kawamura T, et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. 2009;24:3068–74.
11. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int. 2006;69:1455–8.
12. Kitagawa T. Lessons learned from the Japanese nephritis screening study. Pediatr Nephrol. 1988;2:256–63.
13. Yamagata K, Iseki K, Nitta K, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12:1–8.
14. Katafuchi R, Ninomiya T, Nagata M, et al. Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011;6:2806–13.
15. Shima Y, Nakanishi K, Hama T, et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol. 2012;27:783–92.
16. Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71:1148–54.
17. Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118:629–39.
18. Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119:1668–77.
19. Novak J, Julian BA, Tomana M, et al. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol. 2008;28:78–87.
20. Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.
21. Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012;23:1579–87.
22. Ieiri N, Hotta O, Sato T, et al. Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy. Clin Exp Nephrol. 2012;16:122–9.
23. Hotta O, Furuta T, Chiba S, et al. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis. 2002;39:493–502.
24. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104:73–81.
25. Matousovic K, Novak J, Yanagihara T, et al. IgA1-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant. 2006;21:2478–84.
26. Hollander M, Wolfe DA. Nonparametric statistical methods. 2nd ed. Hoboken: Wiley-Interscience; 1999.
27. Clarkson AR, Seymour AE, Thompson AJ, et al. IgA nephropathy: a syndrome of uniform morphology, diverse clinical features and uncertain prognosis. Clin Nephrol. 1977;8:459–71.
28. D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64:709–27.
29. Gharavi AG, Moldoveanu Z, Wyatt RJ, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol. 2008;19:1008–14.
30. Suzuki H, Suzuki Y, Narita I, et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol. 2008;19:2384–95.
31. Kajiyama T, Suzuki Y, Kihara M, et al. Different pathological roles of toll-like receptor 9 on mucosal B cells and dendritic cells in murine IgA nephropathy. Clin Dev Immunol. 2011;2011:819646. doi:10.1155/2011/819646
32. Sato D, Suzuki Y, Kano T, et al. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant. 2012;27:1090–7.
33. Suzuki Y, Suzuki H, Nakata J, et al. Pathological role of tonsillar B cells in IgA nephropathy. Clin Dev Immunol. 2011;2011:639074. doi:10.1155/2011/639074
34. Jackson S. Immunoglobulin-antiimmunoglobulin interactions and immune complexes in IgA nephropathy. Am J Kidney Dis. 1988;12:425–9.
35. Czerkinsky C, Koopman WJ, Jackson S, et al. Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest. 1986;77:1931–8.
36. González-Cabrero J, Egido J, Sancho J, et al. Presence of shared idiotypes in serum and immune complexes in patients with IgA nephropathy. Clin Exp Immunol. 1987;68:694–702.
37. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol. 2007;96:179–204.